Lucid Diagnostics’ (LUCD) Buy Rating Reaffirmed at BTIG Research

Posted by Geri Gentry on May 16th, 2026

BTIG Research restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a report issued on Friday,Benzinga reports. BTIG Research currently has a $2.50 price target on the stock.

Several other research firms also recently commented on LUCD. Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, March 26th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lucid Diagnostics has an average rating of “Moderate Buy” and a consensus price target of $4.13.

Read Our Latest Stock Report on LUCD

Lucid Diagnostics Price Performance

LUCD stock opened at $0.99 on Friday. The company has a market capitalization of $193.52 million, a PE ratio of -2.11 and a beta of 1.10. Lucid Diagnostics has a 12 month low of $0.95 and a 12 month high of $1.70. The firm’s 50-day moving average is $1.20 and its 200 day moving average is $1.18.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.38 million. Sell-side analysts forecast that Lucid Diagnostics will post -0.22 EPS for the current fiscal year.

Institutional Trading of Lucid Diagnostics

A number of institutional investors have recently modified their holdings of LUCD. Centiva Capital LP bought a new stake in shares of Lucid Diagnostics in the 3rd quarter valued at about $25,000. Sprott Inc. bought a new stake in shares of Lucid Diagnostics in the 3rd quarter valued at about $25,000. SG Americas Securities LLC bought a new stake in shares of Lucid Diagnostics in the 3rd quarter valued at about $26,000. Abel Hall LLC bought a new stake in shares of Lucid Diagnostics in the 4th quarter valued at about $33,000. Finally, JPMorgan Chase & Co. boosted its stake in Lucid Diagnostics by 71,026.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after purchasing an additional 32,672 shares in the last quarter. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.